AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30233140 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide/pantoprazole (100 mg/20 mg) twice daily for 14 days
Number of subjects: 490
Study 30233140 — intervention group
Group type: COMPARATOR
Intervention: naproxen/esomeprazole magnesium (500 mg/20 mg) twice daily for 14 days
Number of subjects: 490
Study 30233140 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide/pantoprazole
Number of subjects: 490
Study 30233140 — intervention group
Group type: COMPARATOR
Intervention: naproxen/esomeprazole magnesium
Number of subjects: 490
Study 30233802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone 801 mg three times daily for 24 weeks
Number of subjects: 0
Study 30233802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30233808 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (900 µg)
Number of subjects: 36
Study 30233812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 0
Study 30233812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 0
Study 30233812 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (both dosing regimens)
Number of subjects: 0
Study 30233812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30234000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit-Plus (activity trackers + weekly emails)
Number of subjects: 120
Study 30234000 — intervention group
Group type: COMPARATOR
Intervention: Fitbit-Only (activity trackers only)
Number of subjects: 120
Study 30234000 — intervention group
Group type: COMPARATOR
Intervention: Fitbit-Plus vs. Fitbit-Only
Number of subjects: 120
Study 30234149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg twice daily after reduction from 10 mg)
Number of subjects: 178
Study 30234149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 mg twice daily)
Number of subjects: 178
Study 30234149 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 178
Study 30234149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib and mycophenolic acid combination
Number of subjects: 178
Study 30234404 — intervention group
Group type: EXPERIMENTAL
Intervention: FMCA + A (fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance)
Number of subjects: 16
Study 30234404 — intervention group
Group type: EXPERIMENTAL
Intervention: FMCA + A
Number of subjects: 16
Study 30234404 — intervention group
Group type: COMPARATOR
Intervention: FMC-A (fludarabine, mitoxantrone, cyclophosphamide followed by alemtuzumab)
Number of subjects: 16
Study 30234410 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair cortisol concentration
Number of subjects: 0
Study 30234410 — intervention group
Group type: COMPARATOR
Intervention: Current literature on hair cortisol
Number of subjects: 0
Study 30234419 — intervention group
Group type: EXPERIMENTAL
Intervention: HAT TRICK program (12 weekly sessions promoting healthy eating, active living, and social connectedness)
Number of subjects: 23
Study 30234539 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal accelerometer
Number of subjects: 7
Study 30234539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal capnometer
Number of subjects: 7
Study 30234539 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal pressure transducer
Number of subjects: 7
Study 30234539 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal thermistor
Number of subjects: 7
Study 30234539 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritracheal microphone
Number of subjects: 7
Study 30234539 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpulmonary electrical impedance
Number of subjects: 7
Study 30234539 — intervention group
Group type: EXPERIMENTAL
Intervention: Photoplethysmography
Number of subjects: 7
Study 30234617 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (APDs)
Number of subjects: 683
Study 30235235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil 10 mg
Number of subjects: 10
Study 30235661 — intervention group
Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence perfusion imaging using indocyanine green (ICG) after graft creation and thoracic pull-up
Number of subjects: 70
Study 30235661 — intervention group
Group type: EXPERIMENTAL
Intervention: ICG angiography (ICGA)
Number of subjects: 70
Study 30235940 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) adherence measured by time-to-refill
Number of subjects: 420
Study 30235940 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver education level (secondary or higher)
Number of subjects: 420
Study 30235940 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver education level (elementary education only)
Number of subjects: 420
Study 30235940 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) adherence
Number of subjects: 420
Study 30236025 — intervention group
Group type: EXPERIMENTAL
Intervention: α-1 antitrypsin (AAT) therapy, administered as multiple repeated infusions (up to 36) over a long-term period (up to 5 years)
Number of subjects: 0
Study 30236149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 50
Study 30236149 — intervention group
Group type: COMPARATOR
Intervention: Self-monitored exercise
Number of subjects: 50
Study 30236247 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging after successful sciatic block
Number of subjects: 63
Study 30236247 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging after failed sciatic block
Number of subjects: 63
Study 30236247 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging for predicting successful sciatic block
Number of subjects: 63
Study 30236247 — intervention group
Group type: EXPERIMENTAL
Intervention: BFI increase of the big toe at 10 min after sciatic block
Number of subjects: 63
Study 30236252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ventilation with high tidal volume (8.8 ml/kg) and low PEEP, without recruitment manoeuvres.
Number of subjects: 2012
Study 30236390 — intervention group
Group type: EXPERIMENTAL
Intervention: Late ventricular arrhythmias (VAs) in LVAD recipients
Number of subjects: 494
Study 30236390 — intervention group
Group type: EXPERIMENTAL
Intervention: VT-LVAD score
Number of subjects: 494
Study 30236749 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400mg at Weeks 0, 2 and 4, then 200mg every 2 weeks
Number of subjects: 77
Study 30236749 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 77
Study 30237023 — intervention group
Group type: EXPERIMENTAL
Intervention: ExoDx Prostate (IntelliScore) (EPI) urine exosome gene expression assay
Number of subjects: 503
Study 30237265 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning application in analyzing organ involvement
Number of subjects: 0
Study 30237305 — intervention group
Group type: EXPERIMENTAL
Intervention: biweekly α
Number of subjects: 0
Study 30237702 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical risk score (ERS)
Number of subjects: 40
Study 30237702 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-survivors)
Number of subjects: 40
Study 30237899 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training package (KEW) for therapeutic radiographers
Number of subjects: 0
Study 30238609 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 DM patients
Number of subjects: 248
Study 30238609 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 DM patients
Number of subjects: 248
Study 30238609 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 248
Study 30238814 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 vaginal insert 4µg
Number of subjects: 374
Study 30238814 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 vaginal insert 10µg
Number of subjects: 374
Study 30238814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 30239219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Closed Loop (HCL) system (MiniMed™ 670G)
Number of subjects: 29
Study 30239252 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposome injection (VSLI) 2.25 mg/m²
Number of subjects: 44
Study 30239252 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine sulfate liposome injection (VSLI)
Number of subjects: 44
Study 30239559 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium fiber (median dose of ∼10.2 g)
Number of subjects: 1924
Study 30239831 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Number of subjects: 0
Study 30239831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30239831 — intervention group
Group type: EXPERIMENTAL
Intervention: AKAP13
Number of subjects: 0
Study 30239831 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of ERK
Number of subjects: 0
Study 30239831 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition of p38 MAPK
Number of subjects: 0
Study 30239866 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR (Nitrogen Isotope Ratio)
Number of subjects: 153
Study 30239866 — intervention group
Group type: EXPERIMENTAL
Intervention: CIR (Carbon Isotope Ratio)
Number of subjects: 153
Study 30239866 — intervention group
Group type: EXPERIMENTAL
Intervention: Model of animal protein intake based on NIR, CIR, and participant characteristics
Number of subjects: 153
Study 30240327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in arm A (BRCA1/2 mutated)
Number of subjects: 89
Study 30240327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in arm B (unselected)
Number of subjects: 89
Study 30240327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin (7 mg flat dose, later 3.5 mg/m²) in patients with BRCA2 mutations
Number of subjects: 89
Study 30240401 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma smokers/ex-smokers (SAs/ex)
Number of subjects: 0
Study 30240401 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers (SAn)
Number of subjects: 0
Study 30240401 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers with severe asthma (CSA)
Number of subjects: 0
Study 30240401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-smokers with severe asthma (ESA)
Number of subjects: 0
Study 30240401 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-smokers with severe asthma (NSA)
Number of subjects: 0
Study 30240471 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 1200 mg daily for 6 months
Number of subjects: 24
Study 30240471 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe)
Number of subjects: 24
Study 30240471 — intervention group
Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 24
Study 30240852 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg, orally once daily)
Number of subjects: 0
Study 30240852 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care EGFR TKI (gefitinib 250 mg or erlotinib 150 mg, orally once daily)
Number of subjects: 0
Study 30240852 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study 30240852 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care EGFR TKI
Number of subjects: 0
Study 30240937 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily for 16 weeks
Number of subjects: 0
Study 30240937 — intervention group
Group type: EXPERIMENTAL
Intervention: Galcanezumab 5, 50, 120, and 300 mg subcutaneously every 4 weeks, twice
Number of subjects: 0
Study 30240937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30241271 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids (90.7% of patients), with 42.2% receiving weak opioids and 57.8% receiving strong opioids.
Number of subjects: 465
Study 30241271 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients reporting sleep disturbance due to pain.
Number of subjects: 465
Study 30241271 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients reporting problems with pain/discomfort, usual activities, mobility, and anxiety/depression.
Number of subjects: 465
Study 30241271 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine equivalents prescribed (30 mg median daily dose for morphine and tramadol).
Number of subjects: 465
Study 30241526 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteogenomic characterization and integrative genomic analysis; methods included whole exome and transcriptome sequencing and single nucleotide polymorphism array profiling.
Number of subjects: 6
Study 30241550 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD163
Number of subjects: 29
Study 30241550 — intervention group
Group type: EXPERIMENTAL
Intervention: Kupffer cell activation
Number of subjects: 29
Study 30241562 — intervention group
Group type: EXPERIMENTAL
Intervention: Xue-Fu-Zhu-Yu Capsule (XFZYC)
Number of subjects: 120
Study 30241562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30241561 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 102
Study 30241561 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline injection)
Number of subjects: 102
Study 30242306 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (anti-PD-L1), given intravenously every 3 weeks until unacceptable toxic effects or loss of clinical benefit
Number of subjects: 116
Study 30242736 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (200 mg once daily for 6 days)
Number of subjects: 389
Study 30242736 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (600 mg twice daily for 10 days)
Number of subjects: 389
Study 30242747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation according to an algorithm promoting alternatives to continuous infusion of midazolam or propofol (intervention group)
Number of subjects: 1174
Study 30242747 — intervention group
Group type: COMPARATOR
Intervention: Usual sedation practices (control group)
Number of subjects: 1174
Study 30242747 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation according to an algorithm (intervention group)
Number of subjects: 1174
Study 30242790 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure non-invasive ventilation (NIV) with mean inspiratory positive airway pressure: 27 ± 3 cm H2O
Number of subjects: 20
Study 30242790 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 20
Study 30242826 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty syndrome (assessed with Clinical Frailty Scale ≥ 5 points)
Number of subjects: 272
Study 30242826 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 272
Study 30242826 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute mode of admission
Number of subjects: 272
Study 30242826 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 272
Study 30242831 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast metabolizers (n = 65)
Number of subjects: 136
Study 30242831 — intervention group
Group type: COMPARATOR
Intervention: Slow metabolizers (n = 71)
Number of subjects: 136
Study 30242831 — intervention group
Group type: EXPERIMENTAL
Intervention: Both fast and slow metabolizers
Number of subjects: 136
Study 30242831 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2A6 normal genotype (n = 82)
Number of subjects: 136
Study 30242831 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2A6 reduced genotype (n = 42)
Number of subjects: 136
Study 30243203 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Number of subjects: 70
Study 30243203 — intervention group
Group type: EXPERIMENTAL
Intervention: KINARM robot assessments
Number of subjects: 70
Study 30243299 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (GnRHα) followed by human menopausal gonadotropin (hMG) and human chorionic gonadotropin (hCG)
Number of subjects: 35
Study 30243299 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients without treatment)
Number of subjects: 35
Study 30243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Extubation failure (defined as need for reintubation within 48 hours)
Number of subjects: 1514
Study 30243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation for coma
Number of subjects: 1514
Study 30243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation for acute respiratory failure
Number of subjects: 1514
Study 30243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of strong cough
Number of subjects: 1514
Study 30243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1514
Study 30243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of ventilation > 8 days
Number of subjects: 1514
Study 30243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Copious secretions
Number of subjects: 1514
Study 30243304 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obese status
Number of subjects: 1514
Study 30243304 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score ≥ 8
Number of subjects: 1514
Study 30243304 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU mortality
Number of subjects: 1514
Study 30243412 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management with financial incentives
Number of subjects: 22
Study 30243412 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management for substance use-related behaviors
Number of subjects: 22
Study 30243412 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall inclusion of contingency management
Number of subjects: 22
Study 30243418 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (various formulations: oral, injection, implant)
Number of subjects: 338
Study 30243418 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily buprenorphine formulations (tablet or film)
Number of subjects: 338
Study 30243418 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly or monthly injection
Number of subjects: 338
Study 30243418 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-annual implant
Number of subjects: 338
Study 30243418 — intervention group
Group type: COMPARATOR
Intervention: Past buprenorphine prescription
Number of subjects: 338
Study 30243566 — intervention group
Group type: EXPERIMENTAL
Intervention: TUS examination pre-talc and post-talc instillation
Number of subjects: 18
Study 30243566 — intervention group
Group type: EXPERIMENTAL
Intervention: TUS scoring by independent assessors
Number of subjects: 18
Study 30243800 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab alone
Number of subjects: 0
Study 30243800 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab in combination with Tremelimumab
Number of subjects: 0
Study 30243800 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30243817 — intervention group
Group type: EXPERIMENTAL
Intervention: All-night fMRI sleep studies on Night 2
Number of subjects: 12
Study 30244023 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30244099 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 9
Study 30244099 — intervention group
Group type: COMPARATOR
Intervention: Autologous control subjects
Number of subjects: 9
Study 30244215 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure to contacts
Number of subjects: 79
Study 30244215 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing of contacts
Number of subjects: 79
Study 30244215 — intervention group
Group type: EXPERIMENTAL
Intervention: Results received by contacts
Number of subjects: 79
Study 30244215 — intervention group
Group type: EXPERIMENTAL
Intervention: HBsAg-positive results among tested contacts
Number of subjects: 79
Study 30244215 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with disclosure
Number of subjects: 79
Study 30244215 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to disclosure and testing
Number of subjects: 79
Study 30244215 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with HIV-related stigma
Number of subjects: 79
Study 30244344 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic assisted transabdominal retromuscular umbilical prosthetic repair (r-TARUP) using a 15×15 cm self-fixating mesh
Number of subjects: 41
Study 30244381 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm post-ischemic flow-mediated vasodilation
Number of subjects: 71
Study 30244381 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin microvascular reactivity (sodium nitroprusside)
Number of subjects: 71
Study 30244381 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin microvascular reactivity (heating)
Number of subjects: 71
Study 30244381 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse wave reflection changes
Number of subjects: 71
Study 30244381 — intervention group
Group type: EXPERIMENTAL
Intervention: Subendocardial viability ratio
Number of subjects: 71
Study 30244381 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial function indices
Number of subjects: 71
Study 30244613 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole as adjunctive treatment
Number of subjects: 0
Study 30244975 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 30245150 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30245163 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) of nucleus accumbens (NAc) and anterior limb of the internal capsule (ALIC)
Number of subjects: 8
Study 30245189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (20 mg twice daily)
Number of subjects: 19
Study 30245572 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP optimization using esophageal balloon (ESO Group)
Number of subjects: 25
Study 30245572 — intervention group
Group type: COMPARATOR
Intervention: Best achieved static effective compliance (Cstat Group)
Number of subjects: 25
Study 30245572 — intervention group
Group type: EXPERIMENTAL
Intervention: ESO Group
Number of subjects: 25